Mark N Wass
Overview
Explore the profile of Mark N Wass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
7483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parra R, Wass M, Munholland S, Wiper M, Kovats D, Pantano L, et al.
Bioinform Adv
. 2025 Feb;
5(1):vbae204.
PMID: 39927293
The first ISCB LGBTQI+ Symposium, held during Pride Month in 2024, marked a significant milestone for the International Society for Computational Biology (ISCB) community to promote diversity. This event aimed...
2.
Cinatl Jr J, Wass M, Michaelis M
Front Pharmacol
. 2024 Oct;
15:1455870.
PMID: 39469622
There is clinical evidence showing that the root extract EPs 7630 is a safe and effective treatment for a range of acute infectious respiratory illnesses. Moreover, EPs 7630 has been...
3.
Henry S, Webster C, Shaw L, Torres N, Jobson M, Totzke B, et al.
J Infect Dis
. 2024 Jul;
230(1):e149-e158.
PMID: 39052707
Background: Cytochrome bd complexes are respiratory oxidases found exclusively in prokaryotes that are important during infection for numerous bacterial pathogens. Methods: In silico docking was employed to screen approved drugs...
4.
Bernacchia L, Paris A, Gupta A, Charman R, McGreig J, Wass M, et al.
Protein Sci
. 2024 Mar;
33(4):e4948.
PMID: 38501485
Increasing antimicrobial drug resistance represents a global existential threat. Infection is a particular problem in immunocompromised individuals, such as patients undergoing cancer chemotherapy, due to the targeting of rapidly dividing...
5.
Calnan M, Kirchin S, Roberts D, Wass M, Michaelis M
Pharmacol Res
. 2023 Dec;
199:107043.
PMID: 38128855
In the life sciences, there is an ongoing discussion about a perceived 'reproducibility crisis'. However, it remains unclear to which extent the perceived lack of reproducibility is the consequence of...
6.
Bojkova D, Bechtel M, Rothenburger T, Kandler J, Hayes L, Olmer R, et al.
J Med Virol
. 2023 Mar;
95(3):e28686.
PMID: 36938992
Recent findings in permanent cell lines suggested that SARS-CoV-2 Omicron BA.1 induces a stronger interferon response than Delta. Here, we show that BA.1 and BA.5 but not Delta induce an...
7.
Bojkova D, Zoller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, et al.
J Med Virol
. 2023 Mar;
95(3):e28652.
PMID: 36897017
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited...
8.
Reddin I, Fenton T, Wass M, Michaelis M
Pharmacol Res
. 2023 Jan;
188:106671.
PMID: 36681368
Cancer drug development is hindered by high clinical attrition rates, which are blamed on weak predictive power by preclinical models and limited replicability of preclinical findings. However, the technically feasible...
9.
Bojkova D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler J, et al.
iScience
. 2023 Jan;
26(2):105944.
PMID: 36644320
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for monitoring the replication of SARS-CoV-2 isolates from...
10.
Bojkova D, Bechtel M, Rothenburger T, Steinhorst K, Zoller N, Kippenberger S, et al.
N Engl J Med
. 2022 Dec;
388(3):279-281.
PMID: 36577096
No abstract available.